MNKD

3.79

3.81% -0.15

Dopo l'orario di chiusura: 3.86 0.07 +1.85%

Mannkind Corp (MNKD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché MNKD Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.94

Aprire:

$3.9

Volume 24 ore:

3.21M

Relative Volume:

0.72

Capitalizzazione di mercato:

$1.22B

Reddito:

$360.78M

Utile/perdita netta:

$-23.91M

Rapporto P/E:

-48.53

EPS:

-0.0781

Flusso di cassa netto:

$13.07M

1 W Prestazione:

-4.29%

1M Prestazione:

-3.56%

6M Prestazione:

+45.21%

1 anno Prestazione:

-31.96%

Intervallo 1D:

$3.76

$3.90

Intervallo di 1 settimana:

$3.76

$4.36

Portata 52W:

$2.23

$6.51

Mannkind Corp Stock (MNKD) Company Profile

Nome

Mannkind Corp

Settore

Healthcare (1069)

Industria

Biotechnology (595)

Telefono

818-661-5000

Indirizzo

1 CASPER STREET, DANBURY, CA

Dipendente

592

Cinguettio

@MannKindCorp

Prossima data di guadagno

2026-11-04

Ultimi documenti SEC

MNKD's Discussions on Twitter

Compare MNKD vs VRTX, REGN, ARGX, MRNA, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MNKD Mannkind Corp	3.79	1.27B	360.78M	-23.91M	13.07M	-0.0781
VRTX Vertex Pharmaceuticals Inc	514.56	132.08B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	793.26	83.15B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	984.04	62.71B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	136.62	54.14B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	203.35	44.51B	742.00K	-1.37B	-1.07B	-7.0731

Mannkind Corp Stock (MNKD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-27	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-11-24	Iniziato	Truist	Buy
2025-11-13	Iniziato	Leerink Partners	Outperform
2025-10-20	Iniziato	Wells Fargo	Overweight
2025-10-10	Iniziato	Leerink Partners	Outperform
2025-07-16	Ripresa	H.C. Wainwright	Buy
2025-04-10	Iniziato	Mizuho	Outperform
2025-02-10	Iniziato	Wedbush	Outperform
2024-12-20	Iniziato	Wells Fargo	Overweight
2024-12-19	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2024-09-09	Ripresa	Leerink Partners	Outperform
2024-06-13	Iniziato	Rodman & Renshaw	Buy
2023-10-10	Iniziato	Wedbush	Outperform
2021-05-14	Iniziato	RBC Capital Mkts	Sector Perform
2019-12-24	Iniziato	Oppenheimer	Outperform
2019-10-25	Iniziato	Cantor Fitzgerald	Overweight
2019-05-14	Iniziato	BTIG Research	Buy
2019-03-04	Iniziato	SVB Leerink	Outperform
2019-02-22	Iniziato	SVB Leerink	Outperform
2018-02-28	Downgrade	Maxim Group	Hold → Sell
2017-11-01	Downgrade	Maxim Group	Buy → Hold
2017-10-10	Iniziato	H.C. Wainwright	Buy
2017-10-06	Reiterato	Maxim Group	Buy
2017-08-11	Iniziato	Maxim Group	Buy
2016-05-10	Reiterato	Piper Jaffray	Underweight
2016-05-10	Reiterato	RBC Capital Mkts	Underperform
2016-01-06	Reiterato	Piper Jaffray	Underweight
2016-01-06	Reiterato	RBC Capital Mkts	Underperform
2015-11-04	Downgrade	RBC Capital Mkts	Outperform → Underperform
2015-09-09	Downgrade	Piper Jaffray	Neutral → Underweight
2015-08-03	Reiterato	RBC Capital Mkts	Outperform
2015-05-11	Downgrade	JP Morgan	Neutral → Underweight
2015-05-11	Reiterato	MLV & Co	Hold
2015-04-16	Reiterato	RBC Capital Mkts	Outperform

Mostra tutto

Mannkind Corp Borsa (MNKD) Ultime notizie

04:43 AM

MannKind (NASDAQ: MNKD) director lines up more stock sales under trading plan - Stock Titan

04:43 AM

09:43 AM

CT drugmaker partners on development of inhaled weight-loss treatment - hartfordbusiness.com

09:43 AM

Sep 09, 2026

MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits

Sep 09, 2026

MannKind inks obesity deal with Rose Pharma - The Pharma Letter

Sep 09, 2026

Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule - Benzinga

Sep 09, 2026

MannKind signs global GLP-1 inhalation collaboration deal - grafa.com

Sep 09, 2026

MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching - finance.yahoo.com

Sep 09, 2026

MNKD Looks 44.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus

Sep 09, 2026

MNKD Looks 44.2% Undervalued on GF Value™ Amid Speculative Growth Concerns - GuruFocus

Sep 09, 2026

MannKind partners with Rose Pharma on inhaled GLP-1 therapy By Investing.com - Investing.com India

Sep 09, 2026

MannKind partners with Rose Pharma on inhaled GLP-1 therapy - Investing.com

Sep 09, 2026

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management - The Manila Times

Sep 09, 2026

MannKind and Rose Pharma Enter Worldwide Collaboration to Develop Inhaled ROSE-010 Technosphere for Weight Management - Quiver Quantitative

Sep 09, 2026

A rapid-acting, short-duration inhaled treatment is being developed for weight management - Stock Titan

Sep 09, 2026

Sep 06, 2026

MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits

Sep 06, 2026

Sep 05, 2026

Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us

Sep 05, 2026

Sep 04, 2026

MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits

Sep 04, 2026

Sep 02, 2026

MannKind to Present at Upcoming Investor Conferences - The Manila Times

Sep 02, 2026

Aug 25, 2026